Last reviewed · How we verify
Synergy for Staphylococcus Skin and Skin Structure Infection — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Garamycin | GENTAMICIN | Merck & Co. | Aminoglycoside Antibacterial | Transient receptor potential cation channel subfamily V member 5 | 1970-01-01 | |
| Gentamicin | Gentamicin Sulfate | Merck & Co. | gentamicin | Dihydrofolate reductase | 1970-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Merck & Co. · 2 drugs in Synergy for Staphylococcus Skin and Skin Structure Infection
- · 1 drug in Synergy for Staphylococcus Skin and Skin Structure Infection
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Synergy for Staphylococcus Skin and Skin Structure Infection:
- Synergy for Staphylococcus Skin and Skin Structure Infection treatment updates — RSS
- Synergy for Staphylococcus Skin and Skin Structure Infection treatment updates — Atom
- Synergy for Staphylococcus Skin and Skin Structure Infection treatment updates — JSON
Cite this brief
Drug Landscape (2026). Synergy for Staphylococcus Skin and Skin Structure Infection — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/synergy-for-staphylococcus-skin-and-skin-structure-infection. Accessed 2026-06-10.
Related
- Synergy for Staphylococcus Skin and Skin Structure Infection full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing